Anagnostics Enters Sales Cooperation with Analis S.A.
News Dec 10, 2012
The Belgian company is specialized on clinical diagnostics and distributes Anagnostics’ innovative laboratory in the areas of drugs of abuse screening, personalized medicine (oncology) and sepsis diagnostics.
Since this summer Analis S.A. from Suarlée (near Namur) offers Anagnostics’ diagnostic products for drugs of abuse screening and personalized medicine.
In the coming months the sales portfolio will be enlarged by tests supporting the diagnosis and therapy of sepsis.
Analis and Anagnostics aim to serve hospitals in the Belux countries by offering truly innovative products and first class service.
“Analis is specialized on clinical diagnostics for a broad and loyal customer base and emphasizes first class support and advice of customers. Therewith Analis is the ideal partner for the distribution of our laboratory tests in Belgium and Luxembourg”, comments Christoph Reschreiter, CEO of Anagnostics Bioanalysis GmbH.
Guy Stukkens, CEO of Analis S.A. is looking forward to the sales cooperation: “We clearly see the trend towards more specific as well as more targeted and faster diagnostics, which is offered by multiplexed diagnostics. Anagnostics reacted on this need perfectly well. With the hyborg device and the test portfolio Anagnostics offers good market opportunities. The fast and efficient testing of drugs of abuse consumption ensures access to therapy institutions. The simple and highly sensitive tests in personalized medicine are particularly advantageous for small and medium sized pathologies, because cost efficiency is ensured even with low sample numbers.”
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE